StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) company profile

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

About ProQR Therapeutics

Pharmaceutical Preparations, SIC 2834

ProQR Therapeutics N.V. is a biopharmaceutical company that discovers and develops therapies using an RNA editing technology platform. The company focuses on advancing preclinical and clinical development programs, including investigational RNA-targeted product candidates such as ultevursen and sepofarsen. Rather than selling commercial treatments directly to end users, ProQR works in collaboration with global pharmaceutical companies, research organizations, and patient foundations. Its partners include Eli Lilly and Company, the Rett Syndrome Research Trust, and the Foundation Fighting Blindness.

The company maintains its corporate headquarters, principal executive offices, and laboratory facilities in Leiden, the Netherlands. Its corporate structure encompasses several entities located in the Netherlands and the United States, including ProQR Therapeutics I Inc. The organization carries out research and clinical testing across geographic regions subject to supervision by health authorities, including the United States Food and Drug Administration and the European Medicines Agency.

Summary of the business section of ProQR Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
ProQR Therapeutics N.V.
Founded
2012
Headquarters
Leiden, Netherlands
Address
Zernikedreef 9
Phone
31 88 166 7000
Website
proqr.com
Employees
59, Dec 31, 2014
Industry
Pharmaceutical Preparations
Incorporated in
P7
Fiscal year ends
December 31
Auditor
KPMG Accountants N.V., Amstelveen, the Netherlands

Stock & identifiers

Ticker
PRQR
Exchange
Nasdaq
IPO date
Sep 19, 2014
Shares outstanding
105M, Dec 31, 2025
Filer category
Accelerated filer
SEC CIK
1612940
CUSIP
N71542109
FIGI
BBG006N8B830
Share class FIGI
BBG006N8B849
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Boer Daniel Anton deChief Executive Officer, Director500,000
Gerardus Johannes PlatenburgChief Scientific Officer, Director824,388
Dennis HomChief Financial Officer–
Bart FiliusDirector300,000
Gylvin Lykke HinschDirector–
Alison Frances LawtonDirector–
Martin Alexander MaierDirector–
Theresa HeggieDirector43,623
Domenico ValerioDirector725,692
Begona Carreno-GomezDirector–
James Samuel ShannonDirector61,538

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 19, 2014
Offer price
$13.00
Securities offered
7,500,000
Gross proceeds
$97.50M
Exchange
Nasdaq
First trading day
Sep 18, 2014
First-day close
$14.73+13.3%
Lock-up ends (est.)
Mar 17, 2015

“The initial public offering price is $13.00 per ordinary share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 3, 2014Name changeName changed from ProQR Therapeutics B.V. to ProQR Therapeutics N.V.
Sep 19, 2014IPOInitial public offering priced (424B4 prospectus)
Sep 16, 2014ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?